Search Clinical Trials
Sponsor Condition of Interest |
---|
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
Tulane University
Cancer
Neoplasm Malignant
Through this award, Michael Hoerger, PhD, MSCR, a psychologist at the Tulane Cancer
Center in Louisiana, will lead a study called EMPOWER 3 designed to test an educational
intervention to help patients understand palliative care, use it, and feel better
emotionally and physically. Participants will1 expand
Through this award, Michael Hoerger, PhD, MSCR, a psychologist at the Tulane Cancer Center in Louisiana, will lead a study called EMPOWER 3 designed to test an educational intervention to help patients understand palliative care, use it, and feel better emotionally and physically. Participants will be adults with serious cancer diagnoses. Participants will be randomized into two groups. Patients in the control group will get enhanced usual care, meaning standard cancer care and several additional healthcare-related brochures. Patients in the intervention group will get enhanced usual care plus an educational video developed by the investigators and other materials designed to increase understanding and use of palliative care. Family members of patients in the intervention group may also attend if desired. The investigators will track participants' understanding of palliative care, attitudes toward palliative care, symptoms over 6 months of follow-up, and palliative care utilization. Type: Interventional Start Date: Mar 2021 |
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients1
NRG Oncology
Metastatic Malignant Neoplasm in the Bone
Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8
This phase III trial compares less intense hormone therapy and radiation therapy to usual
hormone therapy and radiation therapy in treating patients with high risk prostate cancer
and low gene risk score. This trial also compares more intense hormone therapy and
radiation therapy to usual hormone t1 expand
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score. Type: Interventional Start Date: Dec 2020 |
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fib1
United Therapeutics
Progressive Pulmonary Fibrosis
Interstitial Lung Disease
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil
in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period. expand
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period. Type: Interventional Start Date: Oct 2023 |
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
American Thrombosis and Hemostasis Network
Hematologic Disorder
Bleeding Disorder
Connective Tissue Disorder
Hemophilia
Thrombosis
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN)
clinical studies, the number of new therapies for all congenital and acquired hematologic
conditions, not just those for bleeding and clotting disorders, is increasing
significantly. Some of the recently FDA-approved1 expand
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7) Type: Observational Start Date: Sep 2020 |
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Gra1
Equillium
Graft Versus Host Disease
GVHD
Acute-graft-versus-host Disease
Acute GVHD
aGVHD
This is a multi-center study to compare the efficacy and safety of itolizumab versus
placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI
involvement, in combination with corticosteroids expand
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids Type: Interventional Start Date: Apr 2022 |
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against
placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52. expand
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52. Type: Interventional Start Date: Jun 2021 |
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
C. R. Bard
Open Midline Laparotomy
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at
the time of midline fascial closure compared to primary suture closure in preventing a
subsequent incisional hernia in subjects at risk for incisional hernia after open midline
laparotomy surgery. expand
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery. Type: Interventional Start Date: Dec 2019 |
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevent1
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
This is an interventional, prospective, international, multicenter, single-arm, Phase 3,
and sequential efficacy and safety study in adolescents and adults with congenital
hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing
elective major surgical procedures. expand
This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures. Type: Interventional Start Date: Jun 2024 |
Von Willebrand Factor in Pregnancy (VIP) Study
University of Washington
Von Willebrand Diseases
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not
have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%,
specific guidance is lacking for delivery planning in terms of how high of a VWF level
should be achieved to reduce bleeding.
T1 expand
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety. Type: Observational Start Date: Oct 2019 |
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Con1
Shanghai Henlius Biotech
Limited-Stage Small Cell Lung Cancer
This study is a randomized, double-blind, multicenter, phase III clinical study to
compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent
radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage
Small Cell Lung Cancer. expand
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer. Type: Interventional Start Date: May 2022 |
Medication Adherence Program
Tulane University
Hypertension
Medication Adherence
Behavior and Behavior Mechanisms
Randomized controlled trial testing the efficacy of the Supporting Tailored Adaptive
change and Reinforcement for Medication Adherence Program (STAR-MAP), a health coaching
approach that aims to improve antihypertensive medication adherence, blood pressure
control, and quality of life. Participants1 expand
Randomized controlled trial testing the efficacy of the Supporting Tailored Adaptive change and Reinforcement for Medication Adherence Program (STAR-MAP), a health coaching approach that aims to improve antihypertensive medication adherence, blood pressure control, and quality of life. Participants (n=402) >=40 years old with a diagnosis of hypertension, uncontrolled blood pressure, and low antihypertensive medication adherence will be recruited through a statewide health insurer, Blue Cross Blue Shield of Louisiana, and randomized to receive either interactive health coaching sessions with medication reminder tools (intervention) or medication reminder tools only (control) over one year. Data will be collected from participants at baseline, 6 months, 12 months, and 24 months using questionnaires, physical measurement (height, weight, blood pressure), a computer-based single-category implicit association test, and laboratory analysis of antihypertensive medication urinary metabolites. Type: Interventional Start Date: Mar 2022 |
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy1
SWOG Cancer Research Network
Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg
Step 2. Patients are followed until they will begin Maintenance and then registered to
Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2
years and Lenalidomide + Daratumumab/rH1 expand
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years. Type: Interventional Start Date: Aug 2019 |
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Eledon Pharmaceuticals
Kidney Transplant Rejection
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in
patients undergoing kidney transplantation. expand
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation. Type: Interventional Start Date: Aug 2023 |
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
ECOG-ACRIN Cancer Research Group
Breast Screening
This randomized phase III trial studies digital tomosynthesis mammography and digital
mammography in screening patients for breast cancer. Screening for breast cancer with
tomosynthesis mammography may be superior to digital mammography for breast cancer
screening and may help reduce the need for a1 expand
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment. Type: Interventional Start Date: Sep 2017 |
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Center for International Blood and Marrow Transplant Research
Hematologic Malignancies
Inherited Disorders of Metabolism
Inherited Abnormalities of Platelets
Histiocytic Disorders
Acute Myelogenous Leukemia (AML or ANLL)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications. expand
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Type: Observational Start Date: Oct 2011 |
Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome
Icahn School of Medicine at Mount Sinai
NAS
This study examines the effects of 6 different music therapy interventions on outcomes
for neonates diagnosed with Neonatal Abstinence Syndrome. expand
This study examines the effects of 6 different music therapy interventions on outcomes for neonates diagnosed with Neonatal Abstinence Syndrome. Type: Interventional Start Date: Nov 2017 |
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effi1
Hemab ApS
Glanzmann Thrombasthenia
The goal of this clinical trial is to Investigate the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with
Glanzmann Thrombasthenia.
The main questions it aims to answer are:
- Parts A, B, and C: To determine the safety and tolerability of HMB-1 expand
The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia. The main questions it aims to answer are: - Parts A, B, and C: To determine the safety and tolerability of HMB-001 - Part A: To establish the dose level(s) and dosing interval(s) of HMB-001 to be investigated in Parts B and C - Parts B and C: To estimate the ability of HMB-001 to prevent the number and severity of bleeds Part A will assess differing singular doses of HMB-001 in small groups of participants. The dose administered to a newly enrolled participant (or groups of participants) may only increase if analysis of data from previous dosing shows it is safe to do so. The planned duration of participation in Part A is approximately 6 months, which consists of a Screening Period, an optional Run-in Observation Period, and a follow-up period of 8 weeks. Part B is similar to Part A as it involves testing different dose levels of HMB-001 in small groups of participants. However, in Part B, HMB-001 is given multiple times over a 3-month period, either weekly, every 2 weeks, or every 4 weeks. Part B consists of a Screening Period, a Run-in Observation Period, a 3-month Treatment Period, and a Safety Follow-up following the last dose of HMB-001. Part C is open to participants from Part B and consists of approximately a 9-month Treatment Period and a Safety Follow-up following the last dose of HMB-001. Type: Interventional Start Date: Dec 2022 |
Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
Tulane University
Hemophilia A
This trial will enroll patients with severe hemophilia A. Experiments will be run in
vitro by spiking patients' blood with different molecules (currently used and
theoretically proposed as adjunctive therapy to emicizumab), therefore no more than
minimal direct risk to patients is expected. This is1 expand
This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by spiking patients' blood with different molecules (currently used and theoretically proposed as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients is expected. This is a pilot preclinical study. Type: Interventional Start Date: Aug 2022 |
The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study
Tulane University
Atrial Fibrillation
The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove
that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF
burden.
Secondary objectives of the study are the following:
- To investigate the impact of catheter ablation on se1 expand
The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF burden. Secondary objectives of the study are the following: - To investigate the impact of catheter ablation on serum pro-thrombotic biomarkers in patients with AF. - To correlate coagulation biomarkers with imaging features such as, the degree of fibrosis found on Late Gadolinium Enhancement Magnetic Resonance Imaging (LGE-MRI) scans, which is a part of standard of care. - To determine baseline values of coagulation and pro-thrombotic biomarkers in the AF population and compare those baseline values with the general population values. - To compare central and peripheral thrombotic biomarkers in patients with atrial fibrillation. Type: Observational Start Date: Sep 2021 |
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Wo1
Harvard School of Public Health (HSPH)
Antiretroviral Toxicity
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in
utero exposure to antiretroviral therapy and/or exposure in the first two months of life
among children born of HIV-infected mothers. expand
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers. Type: Observational Start Date: Mar 2007 |
Promoting Color Brave Conversations in Families
Tulane University
Racism
Child Development
Parents
The objective of this research is to evaluate a multi-module "color brave" app-based
intervention for parents of children in K-2nd grade, that guides them in how to initiate
and proactively engage their children in productive, critical discussions around
race/racism and anti-racism. This study will1 expand
The objective of this research is to evaluate a multi-module "color brave" app-based intervention for parents of children in K-2nd grade, that guides them in how to initiate and proactively engage their children in productive, critical discussions around race/racism and anti-racism. This study will recruit a national sample of parents and their K-2nd grade children. The impact of the intervention will be tested using a rigorous randomized wait-list controlled trial design. The design of the intervention is based on research indicating that among children, positive intergroup contact with outgroup members, including vicarious engagement, can prevent or reduce anti-outgroup bias, in particular, when contact is based on common goals, cooperation rather than competition, and supported by external authorities. To evaluate the effectiveness of the program, a mixed-methods design will be utilized involving collection of a broad range of outcome measures through online questionnaire surveys, one-on-one interviews with parents and children, and parent-child dyadic interviews. Type: Interventional Start Date: Mar 2023 |
Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis
GID BIO, Inc.
Osteoarthritis, Knee
This study is a pivotal study to evaluate the efficacy and safety of a single injection
of autologous adipose-derived SVF produced using the GID SVF-2 device system for
treatment of pain with concomitant improvement in function associated with osteoarthritis
of the knee joint. expand
This study is a pivotal study to evaluate the efficacy and safety of a single injection of autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of pain with concomitant improvement in function associated with osteoarthritis of the knee joint. Type: Interventional Start Date: Oct 2020 |
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pul1
Pliant Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the
efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary
fibrosis (BEACON-IPF). expand
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF). Type: Interventional Start Date: Nov 2023 |
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Lev1
Gilead Sciences
Primary Biliary Cholangitis
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in
Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance
to Ursodeoxycholic Acid (UDCA) expand
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) Type: Interventional Start Date: Sep 2023 |
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the1
Novo Nordisk A/S
Cardiovascular Disease
This study will look at the effects of CagriSema on cardiovascular events (for example
heart attack and stroke) in people living with cardiovascular disease. Participants will
either get CagriSema or a dummy medicine (also called "placebo") which has no effect on
the body. Which treatment participa1 expand
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years. Type: Interventional Start Date: Mar 2023 |